Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Highlights from ASH 2018: Prof. Charles Craddock

We Do Still Transplant CML, Don't We?

Professor Charles Craddock
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK

Charles Craddock summarised the results of alloSCT in all phases of CML and discussed factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimes have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he focused on emerging peri- and post-transplant strategies to improve the outcome.   

Highlights from John Goldman Conference 2018: Prof. Daniela Krause

Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany) 

  • Scientific workshops on imaging and genome editing
  • Novel strategies with new pathways complementing existing TKI therapies
  • Skeleton muscle toxicities induced by TKI's
  • Possible relationship between dopamin receptors and leukemic stem cell receptors
  • Debate on eradicating remaining stem cells
  • Innovative new technologies for monitoring

 {rscomments off}

Highlights from John Goldman Conference 2018: Prof. Jorge Cortes

Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)

  • Update on new studies including TIGER and SPIRIT II 
  • Long-term outcomes from clinical studies on treatment-discontinuation
  • Various aspects on treatment-free-remission such as predictors of success, biomarkers, gene analysis, use of digital PCR, pregnancy
  • New modalities and tools of monitoring patients 
  • Biology of CML and the role of microenvironment and molecular abnormalities

 {rscomments off}

Highlights from John Goldman Conference 2017: Carolina Pavlovsky

Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives

In Spanish:
Perspectivas sobre nuevas estudios clínicos y cómo se transfieren al mundo real - especialmente en países en vía de desarollo
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina

  • Actualización del estudio CML-IV: Seguridad y eficacia de imatinib durante 10 años
  • Actualización del estudio PACE: Uso de ponatinib en segunda y tercera línea
  • Varios estudios clínicos del discontinuación del tratamiento y qué aspectos deberían considerarse en la aplicación práctica
  • Tratamiento de la población pediátrica y el uso de nuevas tecnologías para el monitoreo molecular

 

Keynote Presentations iCMLf Prizes 2017

Keynote presentations from the recipients of the 2017 iCMLf Prizes

At the 19th Annual John Goldman Conference on CML in Estoril the iCMLf Directors awarded the Foundation’s 2017 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

iCMLf Prize recipients 2017

 

 

  • 2017 Goldman Prize: Professor Timothy Hughes
  • 2017 iCMLf Prize: Professor Jerald Radich
  • 2017 Rowley Prize: Professor Tessa Holyoake 

At Tessa’s request, her keynote was presented by Mhairi Copland, Professor of Translational Haematology at the Paul O’ Gorman Leukemia Research Center at the University of Glasgow.

 

Highlights from John Goldman Conference 2017: Prof. Jorge Cortes

Highlights from the John Goldman Conference on CML 2017:
CML experts give their personal perspectives

Perspectives on biology and clinical aspects 
from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)

  • Leukemic stem cells and microenvironment
  • Biomarkers 
  • Conceptual understanding of treatment-free remission 
  • Treatment discontinuation with 2nd generation TKI's
  • Update on the new ELN recommendations
  • Patient-reported outcomes
  • New modalities of monitoring patients
  • Long-term outcomes from various clinical studies